Downregulation of MYCN through PI3K inhibition in mouse models of pediatric neural cancer
The MYCN proto-oncogene is associated with poor outcome across a broad range of pediatric tumors. While amplification of MYCN drives subsets of high risk neuroblastoma and medulloblastoma, dysregulation of MYCN in medulloblastoma (in the absence of amplification) also contributes to pathogenesis. Si...
Main Authors: | Tene Aneka Cage, Yvan eChanthery, Louis eChesler, Matthew eGrimmer, Zachary eKnight, Kevan eShokat, William A Weiss, W. Clay Gustafson |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2015-05-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2015.00111/full |
Similar Items
-
Biological Role of MYCN in Medulloblastoma: Novel Therapeutic Opportunities and Challenges Ahead
by: Sumana Shrestha, et al.
Published: (2021-06-01) -
The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53
by: Joanna S. Yi, et al.
Published: (2021-06-01) -
Targeting MYCN in Molecularly Defined Malignant Brain Tumors
by: Anna Borgenvik, et al.
Published: (2021-01-01) -
Drugging the “Undruggable” MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers
by: Wolpaw, Adam J., et al.
Published: (2021) -
Invasive pressure monitoring saves from tuberculous meningitis with fulminant generalized brain edema
by: George eTrendelenburg, et al.
Published: (2011-11-01)